Overcoming adaptive therapy resistance in AML by targeting immune response pathwaysKatelyn Melgar, Daniel T. Starczynowski, Xiaohu Zhang et al.|Science Translational Medicine|2019Cited by 88
Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profileKenneth J. Wilson, Juan Marugán, Jingbo Xiao et al.|European Journal of Medicinal Chemistry|2018Cited by 17
Discovery of small molecule agonists of the Relaxin Family Peptide Receptor 2María Esteban-López, Alexander I. Agoulnik, Kenneth J. Wilson et al.|Communications Biology|2022Cited by 9
Activation of mitochondrial TRAP1 stimulates mitochondria-lysosome crosstalk and correction of lysosomal dysfunctionFannie W. Chen, Yiannis A. Ioannou, Joanna P. Davies et al.|iScience|2022Cited by 8